OBJECTIVE. This commentary discusses research examining comparisons of locoregional therapy with systemic therapy for unresectable hepatocellular carcinoma (HCC). CONCLUSION. Comparison of patient outcomes after locoregional or systemic therapy for HCC is confounded by selection bias, wherein patients chosen for locoregional therapy usually have better underlying liver function that may contribute to the observed longer survival.
- Chemoembolization, hepatocellular carcinoma
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging